NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
Ysios Capital’s portfolio company Aura Biosciences prices IPO on NASDAQ<
03 Nov 2021

Ysios Capital’s portfolio company Aura Biosciences prices IPO on NASDAQ

Aura Biosciences is the sixth portfolio company of Ysios to be listed on NASDAQ, and the third one this year.
Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer<
02 Nov 2021

Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer

Upcoming Phase 2 trial marks expansion of Galecto pipeline into oncology and provides opportunity for exploring the use of galectin-3 inhibitors in cancer.
Synendos Therapeutics Appoints Scientific Advisory Board<
26 Oct 2021

Synendos Therapeutics Appoints Scientific Advisory Board

Scientific Advisory Board made up of prominent scientists with significant CNS expertise
ONA Therapeutics Strengthens Scientific Leadership Team<
21 Oct 2021

ONA Therapeutics Strengthens Scientific Leadership Team

Expansion of the Scientific Advisory Board with appointments of leading experts in preclinical, translational and clinical drug development.
VarmX awarded funding from the EIC Accelerator to support scale up and manufacturing of VMX-C001<
21 Oct 2021

VarmX awarded funding from the EIC Accelerator to support scale up and manufacturing of VMX-C001

Funding comprises grant financing of up to €2.5 million and up to €15 million in equity investment
CorWave Wins 2021 HealthTech Award<
19 Oct 2021

CorWave Wins 2021 HealthTech Award

CorWave received the Medtech Award, which recognizes a medical device or diagnostic company that has distinguished itself over the past two years.
Kala Pharmaceuticals Announces Appointment of C. Daniel Myers to Board of Directors<
18 Oct 2021

Kala Pharmaceuticals Announces Appointment of C. Daniel Myers to Board of Directors

Mr. Myers will serve as a Class III director, and join both the Compensation and Nominating and Corporate Governance Committee
LAVA Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia<
15 Oct 2021

LAVA Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia

FDA has granted ODD for the company’s CD1d targeted GammabodyTM, LAVA-051, for the treatment of chronic lymphocytic leukemia.
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology<
13 Oct 2021

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

Collaboration combines Intellia’s proprietary genome editing technology platform with SparingVision’s significant ophthalmology expertise
Aura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting<
11 Oct 2021

Aura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting

There have been no related serious adverse events, dose limiting toxicities, or grade 3 adverse events observed during the study.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка